-
Schrödinger receives $57M from Lilly's acquisition of co-founded Ajax Therapeutics
Received ~$57M cash from Eli Lilly's acquisition of Ajax Therapeutics, a company co-founded by Schrödinger.
-
Schrodinger CCO Mannix Aklian departs; Paul Davie returns as interim; guidance reaffirmed
Mannix Aklian ceased as Chief Commercial Officer, Global Head of Software Sales effective May 18, 2026.
-
Schrödinger Q1 ACV $28.4M (+12%), drug disc. rev surges to $22.9M, net loss $60M, FY guide maintained
ACV $28.4M (+12% YoY); software revenue $35.6M (-21%) reflecting hosted transition.
-
Schrödinger reports 2025 revenue $255.9M (+23%), net loss $103.3M; guides 2026 software ACV $218-228M
Software revenue $199.5M (+10.6%); drug discovery revenue $56.4M (+107%) vs $27.2M in 2024.
-
Schrödinger Q3 revenue up 54% to $54.3M; software growth 28%, FY guidance trimmed
Total revenue $54.3M (+54% YoY); software revenue $40.9M (+28%); drug discovery $13.5M.
-
Schrödinger Q2 revenue $54.8M (+16% YoY); narrows net loss; maintains revenue guidance, lowers expense guidance
Total revenue $54.8M (+16% YoY); software revenue $40.5M (+15%); drug discovery $14.2M (+19%).
-
Schrodinger appoints Richie Jain as CFO; Geoffrey Porges departs
Richie Jain named EVP and CFO effective May 16, 2025; previously SVP Strategic Finance.
-
Schrödinger Q1 total revenue $59.6M (+63% YoY); software rev $48.8M; maintains FY guidance
Software revenue $48.8M (+46% YoY); drug discovery revenue $10.7M (+237%) incl $5.7M from Novartis collaboration.
-
Schrödinger Q4 software revenue $79.7M (+16% YoY); 2025 outlook: rev growth 10-15%, drug disc rev $45-50M
Q4 2024 total revenue $88.3M (+19% YoY); software revenue $79.7M (+16% YoY).
-
Schrödinger enters $2.272B collaboration with Novartis; $150M upfront
Upfront payment of $150 million to be paid after HSR waiting period expires.
-
Schrödinger Q3 total revenue $35.3M (-17% YoY); announces $150M upfront Novartis collaboration
Software revenue $31.9M (+10% YoY); drug discovery revenue $3.4M (-75% YoY).
-
Schrödinger Q2 rev $47.3M (+35% YoY); net loss $54.0M; updates FY guidance
Total revenue $47.3M (+35% YoY), software rev $35.4M (+21%), drug discovery $11.9M (+104%). Net loss $54.0M vs income $4.3M YoY.
-
Schrödinger Q1 revenue $36.6M, net loss $54.7M; FDA clears IND for SGR-3515
Total revenue $36.6M (down 44% YoY); software revenue $33.4M (+3.7%).
-
Schrödinger enters ATM equity agreement with Leerink to sell up to $250M of common stock
Up to $250M of common stock may be sold at-the-market through Leerink Partners under new Sales Agreement.
-
Schrödinger Q4 software rev +44% to $68.7M; guides 6-13% software growth in 2024
Q4 software revenue $68.7M (+44% YoY); total revenue $74.1M (+30.4%); net loss $30.7M.
-
Schrödinger Q3 revenue $42.6M (+15% YoY); net loss widens to $62M; updates guidance
Total revenue $42.6M (+15% YoY); software revenue $28.9M (+17%); drug discovery $13.7M (+11%).
-
Schrödinger Q2 revenue falls 8.5% to $35.2M; raises software guidance, cuts drug discovery outlook
GAAP net income of $4.3M vs loss of $47.7M; non-GAAP net loss widened to $56.8M from $43.8M.
-
Schrödinger Q2 revenue $35.2M (-8.5% YoY); raises software revenue guidance, cuts drug discovery outlook
Net income $4.3M vs net loss $47.7M YoY, driven by $45.0M other income and $20.4M tax benefit.
-
Schrodinger enters $250M at-the-market stock offering with SVB Securities
Up to $250M in common stock may be sold through SVB Securities as sales agent.
-
Schrödinger Q1 revenue $64.8M (+33%), net income $129.1M on $147M Nimbus gain
Drug discovery revenue $32.6M (up 109% YoY) includes $25M BMS milestone for SOS1/KRAS program.
-
Schrödinger FY2022 total revenue $181M (+31%); Q4 revenue $56.8M (+23%); net loss widens to $149M
FY2022 total revenue $181.0M (+31% YoY); software revenue $135.6M (+20%), drug discovery $45.4M (+84%).
-
Schrodinger Q3 rev $37M (+24% YoY); Lilly collab up to $425M; FY22 guide narrowed
Q3 total revenue $37.0M (+24% YoY); drug discovery $12.3M (+121%); software $24.7M (+2%)
-
Schrödinger Q2 revenue up 29% YoY to $38.5M; net loss widens to $47.7M, maintains 2022 outlook
Software revenue $30.0M (+25% YoY); drug discovery revenue $8.5M (+48% YoY).
-
Schrödinger stockholders approve 2022 Equity Incentive Plan adding up to 15.6M new shares
Stockholders approved 2022 Equity Incentive Plan, authorizing up to 15,605,822 shares of common stock for awards.
-
Schrödinger Q1 total revenue up 51% to $48.7M; net loss widens to $34.5M
Software revenue $33.1M (+26% YoY); drug discovery revenue $15.6M (+169% YoY).
-
CFO Joel Lebowitz retires; enters transition and consulting agreements effective Feb 28, 2022
Joel Lebowitz retired as CFO and Treasurer effective February 28, 2022.
-
Schrödinger Q4 software revenue $38.6M, up 55% YoY; guides 2022 total revenue $161-181M
Q4 total revenue $46.2M (+40% YoY); software revenue $38.6M (+55% YoY); drug discovery $7.6M.
-
Schrödinger Q3 revenue $29.9M (+16% YoY); net loss $35M vs $3.9M income; lowers drug discovery revenue guidance
Revenue $29.9M (+16% YoY); software revenue $24.3M (+6%), drug discovery $5.6M (up from $2.9M).
-
Schrödinger Q2 revenue up 29% to $29.8M; net loss widens to $34.6M on investment spend
Total revenue $29.8M (+29% YoY); software revenue $24.1M (+15% YoY); drug discovery revenue $5.7M.